Trelegy Ellipta 100 ug/1 (Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate POWDER) 100 ug/1

Trelegy Ellipta 100 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Strength

100 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0887-14) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta 100 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is not intended for the relief of acute bronchospasm or asthma attacks. Patients often ask, 'What is Trelegy Ellipta used for?' It is designed to improve lung function and reduce the frequency of exacerbations in COPD patients.

Side Effects

Common effects of Trelegy Ellipta 100 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience a taste alteration or hoarseness. These effects are generally mild and temporary. It's important to consult a healthcare provider if any effects persist or worsen.

Precautions & Warnings

Trelegy Ellipta 100 ug/1 should be used as directed by a healthcare provider. It is important to rinse your mouth after each use to reduce the risk of throat irritation and oral candidiasis. Patients with a history of asthma should use this inhaler with caution. Always store the inhaler at room temperature and keep it out of reach of children.

Avoid Interactions

Trelegy Ellipta 100 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking. Additionally, the use of alcohol or other respiratory medications should be discussed with a healthcare provider to avoid potential interactions.

Frequently Asked Questions

Trelegy Ellipta 100 ug/1 is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Use Trelegy Ellipta 100 ug/1 as directed by your healthcare provider, typically once daily. Rinse your mouth after each use.

Common side effects may include throat irritation, headache, and a dry mouth. These effects are usually mild and temporary.

Trelegy Ellipta 100 ug/1 is not intended for the treatment of asthma. Consult your healthcare provider for appropriate asthma medications.

Store Trelegy Ellipta 100 ug/1 at room temperature and keep it out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.